Skip to content
VECTOR WIREAI INTELLIGENCE
UTC
Home

FDA Clears Medtronic Hugo Robot for U.S. General Surgery

Expanded 510(k) covers upper- and lower-abdominal general surgery procedures.

The U.S. Food and Drug Administration has cleared Medtronic's Hugo robotic-assisted surgery (RAS) system for general surgery, the company announced on November 17, 20262. The expanded 510(k) clearance extends Hugo beyond its original urology indication into procedures Medtronic estimates account for about 3.5 million U.S. surgeries each year.

The premarket notification covers all upper-abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair, and small-bowel resection. Cleared lower-abdominal procedures are inguinal hernia repair and appendectomy. Medtronic says the combined group represents more than half of all soft-tissue procedures performed annually in the United States.

For hospitals, the clearance allows a single robotic platform to run across a considerably broader range of common operations.

The FDA's AI role in the Hugo ecosystem stays in postoperative case review rather than directing robotic instruments during surgery.

ANALYSIS The general-surgery clearance materially changes Hugo's competitive position in the U.S. market by letting installed systems serve the highest-volume soft-tissue category without requiring hospitals to maintain a separate robotic platform. The explicit boundary keeping AI in postoperative review, not intraoperative guidance, defines the current regulatory envelope for the system's software capabilities.

Was this useful?

The day’s vector, in your inbox.

Vector Wire Daily: one dispatch each publishing day.